NMD3

Across TCGA pan-cancer cohorts, NMD3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NMD3 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher NMD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NMD3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

SCLC, BLCA, and CESC are the cancer types where NMD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
BLCA	OS	Median	III,IV	0.120	0.684	<.001	18	view →
CESC	OS	Median	All	0.103	0.588	.004	12	view →
COAD	OS	Median	All	0.508	0.873	.001	8	view →
SKCM	DFS	Median	II,III,IV	1.000	0.682	.027	4	view →
SARC	DFS	Median	All	0.081	0.632	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NMD3–SCLC (OS)

Open the SCLC breakdown →